Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

14 Jun 2022

Abstract excerpt

To May 2022, the COVID-19 pandemic has claimed more than 6.28 million lives, with more than 524 million confirmed cases worldwide. The recent emergence of highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered another major surge in both confirmed cases and deaths. 1 Ten COVID-19 vaccines have been approved by the World Health Organization (WHO) for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35701541
DOI: 10.1038/s41422-022-00681-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adultsPMID 35701541Read ↗

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b TrialSemantic proximity Read ↗

Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical TrialSemantic proximity Read ↗

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccinesSemantic proximity Read ↗

Immunogenicity and Reactogenicity of Heterologous and Homologous mRNA-1273 and BNT162b2 Vaccination: A Multicenter Non-Inferiority Randomized TrialSemantic proximity Read ↗

COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients with CancerSemantic proximity Read ↗

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscapeSemantic proximity Read ↗

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273Semantic proximity Read ↗

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2Semantic proximity Read ↗

Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical StudySemantic proximity Read ↗

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read ↗

Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variantsSemantic proximity Read ↗

Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty <sup>®</sup>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.